PRODROMOS SAKALOGLOU

Dr. PRODROMOS SAKALOGLOU

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IBIoanna Bouba
Ioanna Bouba
EHElissavet Hatzi
Elissavet Hatzi
PLParis Ladias
Paris Ladias
PSPRODROMOS SAKALOGLOU
PRODROMOS SAKALOGLOU
CKCHARILAOS KOSTOULAS
CHARILAOS KOSTOULAS
Ioannis GeorgiouIoannis Georgiou
Ioannis Georgiou
Applications and indications of assisted reproduction technology are expanding, but every new approach is under scrutiny and thorough consideration. Recently, groups of assisted reproduction experts have presented data that support the clinical use of mosaic preimplantation embryos at the blastocyst stage, previously excluded from transfer. In the light of published contemporary studies, with or without clinical outcomes, there is growing evidence that mosaic embryos have the capacity for further in utero development and live birth. Our in-depth discussion will enable readers to better comprehend current developments. This expansion into the spectrum of ART practices requires further evidence and further theoretical documentation, basic research, and ethical support. Therefore, if strict criteria for selecting competent mosaic preimplantation embryos for further transfer, implantation, fetal growth, and healthy birth are applied, fewer embryos will be excluded, and more live births will be achieved. Our review aims to discuss the recent literature on the transfer of mosaic preimplantation embryos. It also highlights controversies as far as the clinical utilization of preimplantation embryos concerns. Finally, it provides the appropriate background to elucidate and highlight cellular and genetic aspects of this novel direction.

16 December 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
MKMyrto Kastrisiou
Myrto Kastrisiou
GZGeorge Zarkavelis
George Zarkavelis
AKAnastasia Kougioumtzi
Anastasia Kougioumtzi
PSPRODROMOS SAKALOGLOU
PRODROMOS SAKALOGLOU
CKCHARILAOS KOSTOULAS
CHARILAOS KOSTOULAS
Angeliki MagklaraAngeliki Magklara
Angeliki Magklara
The detection of actionable mutations in tumor tissue is a prerequisite for treatment customization in patients with metastatic colorectal cancer (mCRC). Analysis of circulating tumor DNA (ctDNA) for the identification of such mutations in patients’ plasma is an attractive alternative to invasive tissue biopsies. Despite having the high analytical sensitivity required for ctDNA analysis, digital polymerase chain reaction (dPCR) technologies can only detect a very limited number of hotspot mutations, whilst a broader mutation panel is currently needed for clinical decision making. Recent advances in next-generation sequencing (NGS) have led to high-sensitivity platforms that allow screening of multiple genes at a single assay. Our goal was to develop a small, cost- and time-effective NGS gene panel that could be easily integrated in the day-to-day clinical routine in the management of patients with mCRC. We designed a targeted panel comprising hotspots in six clinically relevant genes (KRAS, NRAS, MET, BRAF, ERBB2 and EGFR) and validated it in a total of 68 samples from 30 patients at diagnosis, first and second disease progression. Results from our NGS panel were compared against plasma testing with BEAMing dPCR regarding the RAS gene status. The overall percent of agreement was 83.6%, with a positive and negative percent agreement of 74.3% and 96.2%, respectively. Further comparison of plasma NGS with standard tissue testing used in the clinic showed an overall percent agreement of 86.7% for RAS status, with a positive and negative percent agreement of 81.2% and 92.8%, respectively. Thus, our study strongly supports the validity and efficiency of an affordable targeted NGS panel for the detection of clinically relevant mutations in patients with mCRC.

Verified
Journal Article
Open access
PDF file
PSPRODROMOS SAKALOGLOU
PRODROMOS SAKALOGLOU
LLLeandros Lazaros
Leandros Lazaros
IBIoanna Bouba
Ioanna Bouba
Sofia MarkoulaSofia Markoula
Sofia Markoula
AZAthanasios Zikopoulos
Athanasios Zikopoulos
Ioannis GeorgiouIoannis Georgiou
Ioannis Georgiou
Retrotransposable elements are implicated in genome rearrangements and gene expression alterations that result in various human disorders. In the current study, we sought to investigate the potential effects of long interspersed elements-1 (LINE-1) overexpression on the integrity and methylation of DNA and on the expression of three major pluripotency factors (OCT4, SOX2, NANOG) during the preimplantation stages of human embryo development. Human MI oocytes were matured in vitro to MII and transfected through intracytoplasmic sperm injection (ICSI) either with an EGFP vector carrying a cloned active human LINE-1 retroelement or with the same EGFP vector without insert as control. The occurrence of retrotransposition events was screened by fluorescent microscopy. The in vitro preimplantation development as well as the methylation, pluripotency, and DNA double-strand breaks (DSBs) of the transfected embryos were examined. LINE-1 retrotransposons gave rise to new retrotransposition events in the transfected embryos. LINE-1 injected embryos were characterized by accelerated asymmetrical cell division, multiple cellular fragments, cleavage arrest, and degeneration. Early OCT4 expression remained unaltered, but cleavage arrest and a high fragmentation rate hindered the expression of SOX2/NANOG at the morula stage. Increased DNA DSBs were observed in cleavage-stage blastomeres, while no methylation changes were detected before the cleavage arrest. Our data provide evidence that LINE-1 retrotransposition in human preimplantation embryos may induce DNA DSBs, while at the same time, it appears to interfere with the expression patterns of pluripotency factors. The morphological, structural, and cleavage abnormalities of the transfected embryos show that aberrant retroelement expression may negatively affect human embryo development.

10 December 2024 in Acta Microbiologica Hellenica
Verified
Journal Article
Open access
PDF file
PSPRODROMOS SAKALOGLOU
PRODROMOS SAKALOGLOU
PBPETROS BOZIDIS
PETROS BOZIDIS
KKKonstadina Kourou
Konstadina Kourou
CKCHARILAOS KOSTOULAS
CHARILAOS KOSTOULAS
AGAthanasia Gouni
Athanasia Gouni
KGKonstantina Gartzonika
Konstantina Gartzonika
In early 2020, Greece was affected by the SARS-CoV-2 epidemic, and since then, the continuous emergence of fast-spreading variants has caused surges of new SARS-CoV-2 infections. In this study, we performed genomic, phylogenetic, and epidemiological analyses to investigate the SARS-CoV-2 epidemic in northwestern Greece. From March 2020 to February 2022, nasopharyngeal samples obtained from patients suspected to have COVID-19 were tested for SARS-CoV-2 detection. Complete SARS-CoV-2 genomic sequences were generated from selected positive samples. Northwestern Greece experienced four distinct waves of the epidemic following the first wave, which was mainly observed in Attica and other parts of Greece. The positivity index was rising throughout the pandemic waves in several geographical units, with the highest levels recorded in prominent tourist destinations characterized by high agricultural density. The phylogenetic analyses revealed 34 different lineages, with B.1, B.1.1, B.1.1.305, B.1.1.318, B.1.177, B.1.1.7, B.1.617.2, AY.43, and BA.1 being the most prevalent lineages in the region. Although multiple lineages were co-circulating, each pandemic wave was dominated by a different lineage. The SARS-CoV-2 epidemic in northwestern Greece was characterized by the successive introduction of new lineages, resulting in surges of new SARS-CoV-2 infections.

30 January 2026 in Acta Microbiologica Hellenica
Verified
Journal Article
Open access
PDF file
PSPRODROMOS SAKALOGLOU
PRODROMOS SAKALOGLOU
PBPETROS BOZIDIS
PETROS BOZIDIS
KKKonstadina Kourou
Konstadina Kourou
CKCHARILAOS KOSTOULAS
CHARILAOS KOSTOULAS
AGAthanasia Gouni
Athanasia Gouni
KGKonstantina Gartzonika
Konstantina Gartzonika
The Institutional Review Board Statement and Informed Consent Statement sections in the original publication